Aligos Therapeutics Free Cash Flow (FCF) History (ALGS)

Aligos Therapeutics reported −$80.9M in free cash flow for fiscal 2024, a decrease of $1.9M from the previous fiscal year, with a free cash flow margin of −2239.63%.

View full Aligos Therapeutics company overview

Aligos Therapeutics free cash flow by year

Aligos Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-12-31−$80.9M−$1.9M−2239.63%
20232023-12-31−$79.0M$1.3M−1276.30%
20222022-12-31−$80.3M$36.2M
20212021-12-31−$116.6M−$40.2M
20202020-12-31−$76.3M−$26.8M
20192019-12-31−$49.6M

Aligos Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$49.6M to −$80.9M, a net decrease of $31.3M. Aligos Therapeutics's latest reported quarter, Q1 2023, generated −$22.4M in free cash flow, a decrease of $1.4M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Aligos Therapeutics filings at SEC.gov ↗